切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2019, Vol. 08 ›› Issue (02) : 175 -178. doi: 10.3877/cma.j.issn.2095-3232.2019.02.020

基础研究

Id-1在肝细胞癌中表达及其在肿瘤转移中作用机制探讨
艾军华1, 刘刚1, 程素芬1, 项灯1, 熊振芳2, 时军1,†()   
  1. 1. 330006　南昌大学第一附属医院肝胆移植科
    2. 330006　南昌大学第一附属医院病理科
  • 收稿日期:2019-01-04 出版日期:2019-04-10
  • 通信作者: 时军
  • 基金资助:
    国家自然科学基金地区基金资助项目(81450045)

Expression of Id-1 and its mechanism in the metastasis of hepatocellular carcinoma

Junhua Ai1, Gang Liu1, Sufen Cheng1, Deng Xiang1, Zhenfang Xiong2, Jun Shi1,†()   

  1. 1. Department of Hepatobiliary Transplantation, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
    2. Department of Pathology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
  • Received:2019-01-04 Published:2019-04-10
  • Corresponding author: Jun Shi
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

艾军华, 刘刚, 程素芬, 项灯, 熊振芳, 时军. Id-1在肝细胞癌中表达及其在肿瘤转移中作用机制探讨[J/OL]. 中华肝脏外科手术学电子杂志, 2019, 08(02): 175-178.

Junhua Ai, Gang Liu, Sufen Cheng, Deng Xiang, Zhenfang Xiong, Jun Shi. Expression of Id-1 and its mechanism in the metastasis of hepatocellular carcinoma[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2019, 08(02): 175-178.

目的

探讨分化抑制因子-1（Id-1）在肝细胞癌（肝癌）组织中的表达及其在肿瘤转移中的作用机制。

方法

标本来源于2014年1月至2016年12月在南昌大学第一附属医院接受肝切除的56例肝癌患者组织标本。患者均签署知情同意书，符合医学伦理学规定。其中男41例，女15例；年龄26~79岁，中位年龄55岁。45例癌旁肝组织和21例正常肝组织为对照。采用免疫组化法检测Id-1、E-cadherin、Vimentin和MMP-9表达。两组阳性率比较采用χ2检验，并进行Spearman等级相关分析。

结果

肝癌组织Id-1、E-cadherin、Vimentin、MMP-9表达阳性率分别为86%（48/56）、75%（42/56）、39%（22/56）、84%（47/56），明显高于对照组的62%（41/66）、33%（22/66）、15%（10/66）、47%（31/66）（χ2=8.57，13.62，10.73，11.08；P<0.05)。肿瘤直径>5 cm患者Id-1阳性率为100%（24/24），明显高于直径≤5 cm患者的75%（24/32）；转移患者Id-1阳性率97%（34/35），亦明显高于无转移患者的66%（14/21） （χ2=9.25，10.24；P<0.05）。Id-1表达强度与肝癌分化程度呈负相关（rs=-0.295，P<0.05）。Id-1表达与E-cadherin、MMP-9表达呈负相关（rs=-0.432，-0.326；P<0.05），而与Vimentin表达呈正相关（rs=0.713，P<0.05）。

结论

Id-1在肝癌中高表达，其可能机制为通过诱导上皮-间质转化和降解细胞外基质而促进肝癌侵袭转移。

关键词: 癌，肝细胞, 肿瘤侵润, 肿瘤转移, 上皮细胞-间充质细胞转换
Objective

To investigate the expression of inhibitor of differentiation-1 (Id-1) in hepatocellular carcinoma (HCC) and its mechanism in tumor metastasis.

Methods

Tissue specimens were collected from 56 HCC patients undergoing hepatectomy in the First Affiliated Hospital of Nanchang University from January 2014 to December 2016. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 41 patients were male and 15 female, aged 26-79 years with a median age of 55 years. The para-carcinoma liver tissues from 45 cases and normal liver tissues from 21 healthy subjects were used as controls. The expression levels of Id-1, E-cadherin, Vimentin and MMP-9 were quantitatively measured by immunohistochemistry. The positive rates between two groups were compared by Chi-square test. Spearman's rank correlation analysis was performed.

Results

In HCC tissues, the positive rates of Id-1, E-cadherin, Vimentin and MMP-9 expression were 86%(48/56), 75%(42/56), 39%(22/56) and 84%(47/56), significantly higher compared with 62%(41/66), 33%(22/66), 15%(10/66) and 47%(31/66) in control group (χ2=8.57, 13.62, 10.73, 11.08; P<0.05). The positive rate of Id-1 in patients with tumor diameter >5 cm was 100%(24/24), significantly higher than 75%(24/32) in patients with tumor diameter≤5 cm. The positive rate of Id-1 in patients with tumor metastasis was 97%(34/35), significantly higher than 66%(14/21) in patients without tumor metastasis (χ2=9.25, 10.24; P<0.05). The expression level of Id-1 was negatively correlated with the degree of HCC differentiation (rs=-0.295, P<0.05). The expression level of Id-1 was negatively associated with the expression of E-cadherin and MMP-9 (rs=-0.432, -0.326; P<0.05), whereas positively correlated with the expression of Vimentin (rs=0.713, P<0.05).

Conclusions

Id-1 is highly expressed in HCC tissues probably by inducing epithelial-mesenchymal transition and degrading extracellular matrix, thereby promoting the invasion and metastasis of HCC.

Key words: Carcinoma, hepatocellular, Neoplasm invasiveness, Neoplasm metastasis, Epithelial-mesenchymal transition
图1 肝癌和癌旁组织Id-1表达（免疫组化法×100） 注：a为肝癌组织，b为癌旁组织；Id-1为分化抑制因子-1
表1 Id-1表达表达与肝癌组织分化程度相关性分析（例）
分化程度 Id-1
- + ++
低分化 0 3 10
中分化 1 10 14
高分化 7 10 1
表2 Id-1、E-cadherin、Vimentin和MMP-9表达的相关性（例）
Id-1 E-cadherin Vimentin MMP-9
- + ++ - + ++ - + ++
- 6 1 1 6 3 0 0 3 6
+ 7 13 3 11 7 4 3 7 13
++ 1 6 18 17 4 4 6 13 5
[1]
马莉娟，何金彩，柴泽英．细胞分化抑制因子-1与细胞增殖核抗原Ki-67在宫颈癌中的表达及相关性研究[J]．中国临床药理学杂志，2015，31(8):627-630.
[2]
武雪亮，薛军，王立坤，等．DNA结合分化抑制蛋白1和基质金属蛋白酶9在结直肠癌中的表达及与微血管密度的相关性[J]．中国医学科学院学报，2016，38(6): 696-701.
[3]
Ramachandran A, Vizán P, Das D, et al. TGF-β uses a novel mode of receptor activation to phosphorylate SMAD1/5 and induce epithelial-to-mesenchymal transition[J]. Elife, 2018(7):e31756.
[4]
Engerud H, Tangen IL, Berg A, et al. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors[J]. Br J Cancer, 2014, 111(1):78-84.
[5]
Tsang CM, Cheung KC, Cheung YC, et al. Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma[J]. Biochim Biophys Acta, 2015, 1852(3): 2541-2551.
[6]
Cho Y, Cho EJ, Lee JH, et al. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells[J]. Biomed Pharmacother, 2016(83):607-616.
[7]
Hao L, Liao Q, Tang Q, et al. Id-1 promotes osteosarcoma cell growth and inhibits cell apoptosis via PI3K/AKT signaling pathway[J]. Biochem Biophys Res Commun, 2016, 470(3): 643-649.
[8]
Georgiadou D, Sergentanis TN, Sakellariou S, et al. VEGF and Id-1 in pancreatic adenocarcinoma: prognostic significance and impact on angiogenesis[J]. Eur J Surg Oncol, 2014, 40(10):1331-1337.
[9]
Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15(10):599-616.
[10]
Chu Q, Jiang Y, Zhang W, et al. Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma[J]. Oncotarget, 2016, 7(51): 84658-84665.
[11]
Harada K, Hirohara J, Ueno Y, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan[J]. Hepatology, 2013, 57(5):1942-1949.
[12]
He M, Qin H, Poon TC, et al. Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and RNAs[J]. Carcinogenesis, 2015, 36(9):1008-1018.
[13]
Feng YX, Wang T, Deng YZ, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model[J]. Hepatology, 2011, 53(2):483-492.
[14]
Zhu Q, Yuan B, Qiao GL, et al. Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients[J]. Clin Res Hepatol Gastroenterol, 2016, 40(4):418-427.
[15]
Papatheodoridis GV, Chan HL, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy[J]. J Hepatol, 2015, 62(4):956-967.
[16]
Yang SL, Liu LP, Sun YF, et al. Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis[J]. J Gastroenterol, 2016, 51(7):722-732.
[17]
Alzahrani FA, El-Magd MA, Abdelfattah-Hassan A, et al. Potential effect of exosomes derived from cancer stem cells and MSCs on progression of DEN-induced HCC in rats[J]. Stem Cells Int, 2018:8058979.
[18]
Zhang PF, Li KS, Shen YH, et al. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling[J]. Cell Death Dis, 2016(7):e2201.
[19]
Wan X, Cheng C, Shao Q, et al. CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment[J]. Tumour Biol, 2016, 37(5):6073-6084.
[20]
Kim JS, Choi GH, Jung Y, et al. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines[J]. J Cancer Res Clin Oncol, 2018, 144(8):1487-1501.
[1] 中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识（2024版）[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 313-324.
[2] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[5] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[6] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[7] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[8] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[9] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[10] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[11] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[12] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[13] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[14] 何慧玲, 鲁祖斌, 冯嘉莉, 梁声强. 术前外周血NLR和PLR对结肠癌术后肝转移的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 682-687.
[15] 王向前, 李清峰, 陈磊, 丘文丹, 姚志成, 李熠, 吴荣焕. 姜黄素抑制肝细胞癌索拉非尼耐药作用及其调控机制[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 729-735.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？